What's new? Log in Free sign up

Autonomix Medical, Inc. Common Stock (AMIX)

Company Profile

Company profile

Ticker

AMIX

Exchange

Website

CEO

Mr. Bradley Hauser

Incorporated

Location

Fiscal year end

Sector

Health Care and Social Assistance > Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers

Industry (SIC)

Surgical & Medical Instruments & Apparatus

3M • Stryker • FS KKR Capital • Boston Scientific • Solventum • Becton, Dickinson and • Blackstone Secured Lending Fund • Boardwalk Pipeline Partners • Domtar • Golub Capital BDC ...

Former names

Kitov Pharma Ltd., Kitov Pharmaceuticals Holdings Ltd.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Subsidiaries Lists

IRS number

471607810

AMIX stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Autonomix Medical, Inc. Announces Pricing of $9.0 Million Underwritten Public Offering

Prospectus supplement with pricing info

Notice of effectiveness

IPO registration (amended)

12 Nov 24

Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update

Quarterly report

8 Nov 24

IPO registration

Autonomix Announces Reverse Stock Split

Submission of Matters to a Vote of Security Holders

Latest ownership filings

View all

Cavalry Fund I LP

CVI Investments, Inc.

BioStar Ventures III, L.P.

David Andrew Robins

Change in insider ownership

Financial summary

Financial statements Chart AMIX financial data

Quarter (USD)	Sep 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Mar 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
Cash on hand (at last report)	5.16 mm		5.16 mm
Cash burn (monthly)	1.15 mm		945.33 k
Cash used (since last report)	3.21 mm		2.64 mm
Cash remaining	1.94 mm		2.52 mm
Runway (months of cash)	1.7		2.7

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2024

AMIX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	1	9	-88.9%
Opened positions	1	9	-88.9%
Closed positions	9	0	NEW
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	2.56 mm	99.40 mm	-97.4%
Total shares	2.42 mm	32.99 k	+7223.2%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
BioStar Ventures III	2.42 mm	$2.56 mm	NEW

Largest transactions	Shares	Bought/sold	Change
BioStar Ventures III	2.42 mm	+2.42 mm	NEW
Geode Capital Management	0.00	-20.68 k	EXIT
PNC The PNC Financial Services Group, Inc.	0.00	-5.00 k	EXIT
BLK BlackRock	0.00	-4.43 k	EXIT
Tower Research Capital	0.00	-1.51 k	EXIT
RY Royal Bank of Canada	0.00	-1.00 k	EXIT
Global Retirement Partners	0.00	-200.00	EXIT
NA.R National Bank of Canada	0.00	-150.00	EXIT
WFC Wells Fargo & Company	0.00	-17.00	EXIT
JPM JPMorgan Chase & Co.	0.00	-4.00	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

AMIX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
21 Jun 24	Lori Bisson	Option Common Stock	Grant	Acquire A	No	No	1.328	377,221	500.95 k	1,335,821
21 Jun 24	Klemp Walter V	Option Common Stock	Grant	Acquire A	No	No	1.328	175,452	233.00 k	200,452
21 Jun 24	Trent N. Smith	Option Common Stock	Grant	Acquire A	No	No	1.328	228,087	302.90 k	678,087
18 Jun 24	BioStar Ventures III	Warrant to Purchase Common Stock Common Stock	Buy	Acquire P	No	No	0.028	1,088,000	30.46 k	1,088,000
18 Jun 24	David Andrew Robins	Warrant Common Stock	Buy	Acquire P	Yes	No	0.001	103,990	103.99	110,240

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Autonomix Medical Announces Milestone Achievement Of Design Lock For Radio Frequency Ablation Catheter; Expects To Submit IDE And Commence Clinical Trial In H2 2025 To Support De Novo Application For FDA Approval

First-in-class catheter-based sensing technology designed to sense neuronal signals that indicate pain or disease and destroy those nerves at the sourceCompany expects to submit an Investigational Device Exemption

12 Health Care Stocks Moving In Friday's Pre-Market Session

S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results

Crude Oil Gains Over 1%; Ross Stores Earnings Top Views

Dow Jumps 300 Points; Gap Posts Upbeat Earnings

Press releases

From Benzinga Pro

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment

THE WOODLANDS, TX, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how

Autonomix Medical, Inc. Drives Towards U.S. Pivotal Trial with Appointment of Vice President, Regulatory Affairs and Quality

Continued efforts to build team and infrastructure required to support clinical and regulatory initiatives in anticipation of the FDA approval process for first-in-class catheter-based sensing technology Company remains

Autonomix Medical, Inc. Achieves Design Lock for RF Ablation Catheter Following Successful Completion of Animal Testing, Continuing Progress Toward a U.S. Pivotal Trial in 2025

First-in-class catheter-based sensing technology designed to sense neuronal signals that indicate pain or disease and destroy those nerves at the source Company expects to submit an Investigational Device Exemption

Autonomix Medical, Inc. Announces Closing of $10.0 Million Underwritten Public Offering Including Partial Exercise of Over-Allotment Option

Autonomix Medical, Inc. Announces Pricing of $9.0 Million Underwritten Public Offering

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.